WallStSmart

Encompass Health Corp (EHC)vsMarvell Technology Group Ltd (MRVL)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Marvell Technology Group Ltd generates 38% more annual revenue ($8.19B vs $5.94B). MRVL leads profitability with a 32.6% profit margin vs 9.5%. EHC appears more attractively valued with a PEG of 0.41. EHC earns a higher WallStSmart Score of 70/100 (B).

EHC

Strong Buy

70

out of 100

Grade: B

Growth: 7.3Profit: 7.5Value: 8.0Quality: 5.8
Piotroski: 4/9Altman Z: 2.09

MRVL

Strong Buy

66

out of 100

Grade: B-

Growth: 8.7Profit: 8.0Value: 3.7Quality: 7.0
Piotroski: 5/9Altman Z: 1.80
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

EHCUndervalued (+23.0%)

Margin of Safety

+23.0%

Fair Value

$147.31

Current Price

$102.61

$44.70 discount

UndervaluedFair: $147.31Overvalued

Intrinsic value data unavailable for MRVL.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

EHC3 strengths · Avg: 9.0/10
PEG RatioValuation
0.4110/10

Growing faster than its price suggests

Return on EquityProfitability
24.8%9/10

Every $100 of equity generates 25 in profit

EPS GrowthGrowth
21.2%8/10

Earnings expanding 21.2% YoY

MRVL4 strengths · Avg: 9.3/10
Profit MarginProfitability
32.6%10/10

Keeps 33 of every $100 in revenue as profit

EPS GrowthGrowth
106.3%10/10

Earnings expanding 106.3% YoY

Market CapQuality
$144.42B9/10

Large-cap with strong market position

Revenue GrowthGrowth
22.1%8/10

Revenue surging 22.1% year-over-year

Areas to Watch

EHC0 concerns · Avg: 0/10

No major concerns identified

MRVL4 concerns · Avg: 3.5/10
PEG RatioValuation
1.844/10

Expensive relative to growth rate

Price/BookValuation
9.8x4/10

Trading at 9.8x book value

Altman Z-ScoreHealth
1.804/10

Grey zone — moderate risk

P/E RatioValuation
53.8x2/10

Premium valuation, high expectations priced in

Comparative Analysis Report

WallStSmart Research

Bull Case : EHC

The strongest argument for EHC centers on PEG Ratio, Return on Equity, EPS Growth. PEG of 0.41 suggests the stock is reasonably priced for its growth.

Bull Case : MRVL

The strongest argument for MRVL centers on Profit Margin, EPS Growth, Market Cap. Profitability is solid with margins at 32.6% and operating margin at 18.7%. Revenue growth of 22.1% demonstrates continued momentum.

Bear Case : EHC

No major red flags identified for EHC, but monitor valuation.

Bear Case : MRVL

The primary concerns for MRVL are PEG Ratio, Price/Book, Altman Z-Score. A P/E of 53.8x leaves little room for execution misses.

Key Dynamics to Monitor

EHC profiles as a value stock while MRVL is a growth play — different risk/reward profiles.

MRVL carries more volatility with a beta of 1.82 — expect wider price swings.

MRVL is growing revenue faster at 22.1% — sustainability is the question.

MRVL generates stronger free cash flow (259M), providing more financial flexibility.

Bottom Line

EHC scores higher overall (70/100 vs 66/100). Both earn "Strong Buy" and "Strong Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Encompass Health Corp

HEALTHCARE · MEDICAL CARE FACILITIES · USA

Encompass Health Corporation offers in-home and post-acute health care services in the United States. The company is headquartered in Birmingham, Alabama.

Marvell Technology Group Ltd

TECHNOLOGY · SEMICONDUCTORS · USA

Marvell Technology, Inc. designs, develops, and sells analog, mixed-signal, digital signal processing, and integrated and independent integrated circuits. The company is headquartered in Wilmington, Delaware.

Visit Website →

Want to dig deeper into these stocks?